AI specialist Exscientia signs drug discovery tie-up with BayerUK artificial intelligence company Exscientia has added another big pharma company to its partner roster, with Bayer seeking Share XAI specialist Exscientia signs drug discovery tie-up with Bayerhttps://pharmaphorum.com/news/ai-specialist-exscientia-signs-drug-discovery-tie-up-with-bayer/
SidekickHealth begins PAD partnership with BayerNordic digital therapeutics company SidekickHealth has begun a strategic partnership with German pharma Bayer to provide a digital Share XSidekickHealth begins PAD partnership with Bayerhttps://pharmaphorum.com/news/sidekickhealth-begins-pad-partnership-with-bayer/
Novartis’ blockbuster hope Beovu clears EMA advisory panelNovartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green Share XNovartis’ blockbuster hope Beovu clears EMA advisory panelhttps://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/
Merck/Bayer set to challenge Novartis in heart failure after phase 3 trial successMerck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, Share XMerck/Bayer set to challenge Novartis in heart failure after phase 3 trial successhttps://pharmaphorum.com/news/merck-bayers-heart-failure-drug-on-target-at-phase-3/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
Which big pharma firms are best at digital?New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital Share XWhich big pharma firms are best at digital?https://pharmaphorum.com/views-analysis-digital/which-big-pharma-firms-are-best-at-digital/
FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention useBayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA Share XFDA approves Bayer/Janssen’s Xarelto in new blood clot prevention usehttps://pharmaphorum.com/news/fda-approves-bayer-janssens-xarelto-in-new-blood-clot-prevention-use/
Bayer chooses UK for its AI-focused R&D hubBayer has continued its policy of setting up R&D hubs to get closer to innovative companies with a Share XBayer chooses UK for its AI-focused R&D hubhttps://pharmaphorum.com/news/bayer-chooses-uk-for-its-artificial-intelligence-focused-rd-hub/
Novartis’ new eye drug undercuts Bayer’s rival with fewer injectionsThe FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s Share XNovartis’ new eye drug undercuts Bayer’s rival with fewer injectionshttps://pharmaphorum.com/news/novartis-new-eye-drug-undercuts-bayers-rival-with-less-frequent-dosing/
